Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Public ClinicalTrials.gov record NCT04509700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.
Study identification
- NCT ID
- NCT04509700
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Interventions
- Parsaclisib Drug
- parsaclisib + itacitinib Drug
- parsaclisib + ruxolitinib Drug
- parsaclisib + ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2020 (Actual)
- Primary completion
- Nov 5, 2026 (Estimated)
- Completion
- Nov 5, 2026 (Estimated)
- Last update posted
- Jun 25, 2026
2020 – 2026
United States locations
- U.S. sites
- 26
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Uab Comprehensive Cancer Center | Birmingham | Alabama | 35233 | — |
| University of Alabama At Birmingham | Birmingham | Alabama | 35233 | — |
| Mayo Clinic Rochester | Phoenix | Arizona | 85054 | — |
| University of Arizona Cancer Center-Out Pt. | Tucson | Arizona | 85719 | — |
| City of Hope National Medical Center | Duarte | California | 31010 | — |
| California Cancer Associates For Research and Excellence | Fresno | California | 93720 | — |
| Innovative Clinical Research Institute | Long Beach | California | 90805 | — |
| Rocky Mountain Cancer Center | Aurora | Colorado | 80012 | — |
| Rush University Medical Center-Consultants in Hematology | Chicago | Illinois | 60612 | — |
| University of Kansas Hospital Authority | Westwood | Kansas | 66205 | — |
| Rcca Md, Llc | Bethesda | Maryland | 20817 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| University of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Hattiesburg Clinic Hematology | Hattiesburg | Mississippi | 39401 | — |
| Saint Luke'S Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| Hca Midwest Health-Research Medical Center | Kansas City | Missouri | 66211 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| University Hospitals Case Medical Center | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
| Knight Cancer Institute At Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Baylor Scott White Univeristy Medical Center | Dallas | Texas | 75246 | — |
| University of Washington-Seattle Cancer Care Alliance | Seattle | Washington | 98109-4405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04509700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04509700 live on ClinicalTrials.gov.